2021
DOI: 10.15562/bmj.v10i1.2261
|View full text |Cite
|
Sign up to set email alerts
|

Purple sweet potato extract and vitamin C increase the proliferation of endothelial progenitor cells from stable coronary artery disease patients

Abstract: Introduction: Endothelial progenitor cell (EPC) numbers are reduced in stable coronary artery disease (CAD), partly due to oxidative stress. This study aimed to evaluate the effect of different antioxidants, purple sweet potato (PSP) extract and vitamin C, on EPC proliferation in stable CAD patients.Methods: Peripheral blood mononuclear cells were isolated and cultivated on fibronectin-coated plates with the colony-forming unit (CFU)-Hill medium for three days. Non-adherent cells were divided into control, PSP… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“… Angiotensin-converting enzyme (ACE), brain-Derived Nuclear Factor (BDNF), NLR family pyrin domain containing 3 (NLRP3), reactive oxygen species (ROS), platelet-derived growth factor (PDGF), sweet potato (SP), vascular cell adhesion molecule (VCAM), vascular endothelial growth factors receptor 2 (VEGFR2). Data source: [ 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 ]. …”
Section: Figurementioning
confidence: 99%
“… Angiotensin-converting enzyme (ACE), brain-Derived Nuclear Factor (BDNF), NLR family pyrin domain containing 3 (NLRP3), reactive oxygen species (ROS), platelet-derived growth factor (PDGF), sweet potato (SP), vascular cell adhesion molecule (VCAM), vascular endothelial growth factors receptor 2 (VEGFR2). Data source: [ 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 ]. …”
Section: Figurementioning
confidence: 99%
“…In addition, in PAH, there is also a decrease in the vasoactive mediator nitric oxide (NO), prostacyclin, and overexpression of the vasoconstrictor endothelin-1, which results in pulmonary artery vasoconstriction. 6 Until now, therapy based on the pathobiology of PAH is still being developed. Various types of drugs are used in PAH patients to inhibit active pulmonary vasoconstriction and prevent progression by improving pulmonary artery remodeling.…”
Section: Introductionmentioning
confidence: 99%